Einzeltreffer — DigiBib

Background: Seroprevalence studies are an alternative approach to estimating the extent of transmission of SARS-CoV-2 and the evolution of the pandemic in different geographical settings. We aimed to determine the SARS-CoV-2 seroprevalence from March 2020 to March 2022 in a rural and urban setting in Kilifi County, Kenya.

Methods: We obtained representative random samples of stored serum from a pregnancy cohort study for the period March 2020 to March 2022 and tested for antibodies against the spike protein using a qualitative SARS-CoV-2 ELISA kit (Wantai, total antibodies). All positive samples were retested for anti-SARS-CoV-2 anti-nucleocapsid antibodies (Euroimmun, ELISA kits, NCP, qualitative, IgG) and anti-spike protein antibodies (Euroimmun, ELISA kits, QuantiVac; quantitative, IgG).

Results: A total of 2,495 (of 4,703 available) samples were tested. There was an overall trend of increasing seropositivity from a low of 0% [95% CI 0-0.06] in March 2020 to a high of 89.4% [95% CI 83.36-93.82] in Feb 2022. Of the Wantai test-positive samples, 59.7% [95% CI 57.06-62.34] tested positive by the Euroimmun anti-SARS-CoV-2 NCP test and 37.4% [95% CI 34.83-40.04] tested positive by the Euroimmun anti-SARS-CoV-2 QuantiVac test. No differences were observed between the urban and rural hospital but villages adjacent to the major highway traversing the study area had a higher seroprevalence.

Conclusion: Anti-SARS-CoV-2 seroprevalence rose rapidly, with most of the population exposed to SARS-CoV-2 within 23 months of the first cases. The high cumulative seroprevalence suggests greater population exposure to SARS-CoV-2 than that reported from surveillance data.

Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Titel:	SARS-CoV-2 seroprevalence in pregnant women in Kilifi, Kenya from March 2020 to March 2022.
Autor/in / Beteiligte Person:	Koech, A ; Omuse, G ; Mugo, AG ; Mwaniki, IG ; Mutunga, JM ; Mukhanya, MW ; Wanje, O ; Mwashigadi, GM ; Katana, GG ; Craik, R ; von Dadelszen P ; Le Doare, K ; Temmerman, M
Link:	Zum Volltext
Zeitschrift:	Frontiers in public health, Jg. 11 (2023-12-19), S. 1292932
Veröffentlichung:	Lausanne : Frontiers Editorial Office, 2023
Medientyp:	academicJournal
ISSN:	2296-2565 (electronic)
DOI:	10.3389/fpubh.2023.1292932
Schlagwort:	Pregnancy Humans Female Kenya epidemiology Cohort Studies SARS-CoV-2 Seroepidemiologic Studies Antibodies, Viral Immunoglobulin G Pregnant Women COVID-19 epidemiology
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Corporate Authors: periCOVID-Africa ; PRECISE Network Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Language: English [Front Public Health] 2023 Dec 19; Vol. 11, pp. 1292932. <i>Date of Electronic Publication: </i>2023 Dec 19 (<i>Print Publication: </i>2023). MeSH Terms: Pregnant Women* ; COVID-19* / epidemiology ; Pregnancy ; Humans ; Female ; Kenya / epidemiology ; Cohort Studies ; SARS-CoV-2 ; Seroepidemiologic Studies ; Antibodies, Viral ; Immunoglobulin G References: Int J Infect Dis. 2022 Jan;114:268-272. (PMID: 34863925) ; BMJ Open. 2022 Jun 9;12(6):e059617. (PMID: 35680266) ; Reprod Health. 2020 Apr 30;17(Suppl 1):51. (PMID: 32354357) ; Vaccine. 2022 Mar 18;40(13):2011-2019. (PMID: 35184925) ; J Health Econ. 2018 Jul;60:118-141. (PMID: 29960097) ; PLoS One. 2023 Jan 5;18(1):e0280109. (PMID: 36603011) ; PLoS One. 2022 Oct 14;17(10):e0265478. (PMID: 36240176) ; Geospat Health. 2017 Nov 03;12(2):552. (PMID: 29239551) ; BMC Public Health. 2006 Apr 10;6:91. (PMID: 16603091) ; Nat Med. 2022 Mar;28(3):504-512. (PMID: 35027756) ; Front Immunol. 2020 Oct 07;11:575197. (PMID: 33133091) ; Influenza Other Respir Viruses. 2022 Jan;16(1):7-13. (PMID: 34611986) ; Vaccines (Basel). 2022 Jul 22;10(8):. (PMID: 35893818) ; BMJ Glob Health. 2022 Aug;7(8):. (PMID: 35998978) ; Wellcome Open Res. 2021 Sep 3;6:220. (PMID: 35600250) ; J Virol. 2021 Jan 13;95(3):. (PMID: 33144321) ; Nat Commun. 2021 Jun 25;12(1):3966. (PMID: 34172732) ; Clin Infect Dis. 2022 Jan 29;74(2):288-293. (PMID: 33893491) ; Lancet Infect Dis. 2020 May;20(5):533-534. (PMID: 32087114) ; Open Forum Infect Dis. 2021 Jun 12;8(7):ofab314. (PMID: 34660838) ; BMJ. 2020 Sep 1;370:m3320. (PMID: 32873575) ; Reprod Health. 2020 Apr 30;17(Suppl 1):54. (PMID: 32354368) ; Indian J Med Res. 2020 May;151(5):419-423. (PMID: 32611913) ; BMJ Open. 2021 Nov 24;11(11):e055834. (PMID: 34819290) ; Euro Surveill. 2020 Oct;25(42):. (PMID: 33094717) ; AJOG Glob Rep. 2022 Feb;2(1):100049. (PMID: 35005663) ; JAMA Pediatr. 2021 Aug 1;175(8):817-826. (PMID: 33885740) ; J Clin Microbiol. 2021 Apr 20;59(5):. (PMID: 33574119) Grant Information: MC_UU_00027/5 United Kingdom MRC_ Medical Research Council; U54 TW012089 United States TW FIC NIH HHS Contributed Indexing: Investigator: B Freyne; K Kawaza; S Lissauer; H Sommerfelt; M Etti; P Musoke; R Mboizi; S Cose; V Nankabirwa; L Hookham; J Ouma; G Rukondo; M Cochet; M Voysey; L Cantrell; P Okiro; C Juma; M Ochieng; E Mwadime; E Sevene; C Tchavana; S Macuacua; A Vala; H Boene; L Quimice; S Maculuve; E Macete; I Mandomando; C Carillho; U D'Alessandro; A Roca; H Jah; A Prentice; M Martinez-Alvarez; B Diallo; A Sesay; S Suso; B Njie; F Touray; Y Idris; F Kongira; MF Ndure; G Gabbidon; L Gibba; A Bah; Y Bah; LA Magee; H Mistry; ML Volvert; T Mendy; L Poston; J Sandall; R Tribe; S Moore; TT Salisbury; D Russell; PT Makanga; L Makacha; R Mlambo; A Papageorghiou; A Noble; H Blencowe; V Filippi; J Lawn; M Silver; J Waiswa; U Gazeley; J Cartwright; G Whitley; S Krishna; M Vidler; JL Li; J Bone; MMW Kinshella; D Tu; A Sandhu; K Pickerill; B Barratt ; Keywords: COVID-19; Kenya; SARS-CoV-2; antibodies; pregnancy; seroprevalence Substance Nomenclature: 0 (Antibodies, Viral) ; 0 (Immunoglobulin G) Entry Date(s): Date Created: 20240103 Date Completed: 20240105 Latest Revision: 20240501 Update Code: 20240501 PubMed Central ID: PMC10760635

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

SARS-CoV-2 seroprevalence in pregnant women in Kilifi, Kenya from March 2020 to March 2022.